Viking Therapeutics, Inc.
VKTX
$31.32
-$0.40-1.26%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -268.33% | -227.05% | -139.43% | -77.32% | -36.83% |
| Total Depreciation and Amortization | 5.74% | 24.57% | 44.19% | 41.89% | 30.27% |
| Total Amortization of Deferred Charges | -64.44% | -40.43% | -16.67% | 29.73% | 2.27% |
| Total Other Non-Cash Items | 109.43% | 154.54% | 117.42% | 160.77% | 45.98% |
| Change in Net Operating Assets | 558.45% | 423.16% | -213.42% | -143.27% | -177.59% |
| Cash from Operations | -154.00% | -217.45% | -202.46% | -112.02% | -144.20% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 1,195.76% | 161.69% | 151.96% | 124.57% | 95.27% |
| Cash from Investing | 1,195.76% | 161.69% | 151.96% | 124.57% | 95.27% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1,201.17% | -88.32% | -99.64% | -99.33% | -99.26% |
| Repurchase of Common Stock | -- | -- | 100.00% | 100.00% | 100.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 1,201.17% | -87.52% | -99.62% | -99.28% | -99.22% |
| Foreign Exchange rate Adjustments | 107.07% | 94.59% | -279.17% | -80.95% | -43.48% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 150.86% | 582.43% | 280.10% | 60.81% | -188.95% |